XLRN News and Press, Acceleron Pharma Inc. From 05/01/20

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of Bristol-Myers Squibb (NYSE: BMY ) and development partner Acceleron Pharma's (NASDAQ: XLRN ) Reblozyl (luspatercept) for the treatment of: More news on: Bristol-Myers Squibb Company, Ac...

Recommendation for approval based on results from pivotal Phase 3 MEDALIST and BELIEVE studies Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency h...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

The most important thing is to survive the outbreak. Thereafter, for our portfolio to survive too so it can do well when the situation is favorable. Market Pulse The stock market remains unsettled and vulnerable to sharp declines. Over the last two weeks, the market has forcefully steppe...

The FDA designates Acceleron Pharma's (NASDAQ: XLRN ) sotatercept Breakthrough Therapy for the treatment of pulmonary arterial hypertension (PAH), a type of high blood pressure affecting the heart and lungs. More news on: Acceleron Pharma Inc., Healthcare stocks news, Read more ...

Sotatercept granted first FDA Breakthrough Therapy designation in pulmonary arterial hypertension since the Agency established the designation in 2012 Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF...

Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that Jean George is retiring from her position on its Board of Directors. ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) initiated with Buy rating and $149 (51% upside) price target at Jefferies. More news on: Jazz Pharmaceuticals plc, Walgreens Boots Alliance, Inc., Acceleron Pharma Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Acceleron Granted FDA Approval for Luspatercept Label Expansion Acceleron ( XLRN ) reported that the FDA has granted approval for the use of Reblozyl for treating anemia in certain adult patients with very low to intermediate risk myelodysplastic syndromes. These are the patients who did n...

Acceleron Pharma (NASDAQ: XLRN ) and collaboration partner Bristol-Myers Squibb (NYSE: BMY ) announce the FDA nod for Reblozyl (luspatercept-aamt) for the treatment of anemia in certain adult patients with very low-to-intermediate-risk myelodysplastic syndromes who have failed treatment wi...